Minocycline in Huntington's disease: a pilot study. |
| |
Authors: | Madhavi Thomas Tetsuo Ashizawa Joseph Jankovic |
| |
Institution: | Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA. thomasmad@ninds.nih.gov |
| |
Abstract: | Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. |
| |
Keywords: | minocycline Huntington's disease caspase inhibition apoptosis neuroprotection |
|
|